The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -6.50 — distress zone — historically elevated failure riskWatch
- Earnings quality 32/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as NOVAVAX INC reports it. History and quarterly detail are in the app.
- Product sales$685.0M
- Nuvaxovid sales$625.2M
- Licensing, royalties, and other$438.4M
- Milestones$225.0M
- Cost reimbursements$91.6M
Leadership changes
From NOVAVAX INC's own filings, the day they're filed.
- John Trizzino · Chief Operating Officer · departureeff. 2025-06-20
- Richard H. Douglas · Chairperson · appointmenteff. 2025-03-10
- Margaret G. McGlynn · Chairperson · appointmenteff. 2025-03-10
Latest filings
- 8-K · Company announcement2026-05-06
- 10-Q · Quarterly report2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-04-27
- 10-K · Annual report2026-02-26
- 8-K · Company announcement2026-02-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about NOVAVAX INC, every answer cited🔒
- The Intelligence Brief — added when NOVAVAX INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.